Cardinal Health Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Cardinal Health Inc trades at $228.87 (market cap $53.89B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.34. The key difference: Cardinal Health Inc pays a 0.89% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Cardinal Health Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| CAH | YINN | |
|---|---|---|
Market Cap | $53.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $239.71 | $56.62 |
52-Week Low | $146.04 | $21.45 |
Enterprise Value | $58.87B | — |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
YINN, the Direxion Daily FTSE China Bull 3x ETF, trades at $25.25, down 0.43% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral and RSI_6 suggests overbought conditions. Recent sentiment has improved with a Seeking Alpha rating upgrade from bearish to neutral, citing China's relative undervaluation and improved macro backdrop, though concerns remain about the fund's leveraged structure and value trap risks in Chinese equities.
The outlook for YINN is cautiously optimistic, driven by China's tech sector momentum and substantial government AI investment plans. However, significant risks include geopolitical tensions with the U.S., the fund's 3x leverage amplifying volatility, and ongoing regulatory uncertainties. Investors should weigh China's economic stimulus against structural challenges in the market.
Trailing returns across standard periods
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →